A systematic review of literature on diabetes, its potential impacts on hearing loss, and a discussion of the clinical implications. By Emily Urry, PhD and Elizabeth Stewart, AuD, PhD Across a lifespan, an individual’s hearing capacity is influenced by genetic, biological, psychosocial, and environmental factors. These factors can either lead to hearing loss or protect…
What can sugar tax do for health?
Taxing bad habits! or Avoiding bad habits and reducing other taxes for citizens? Regardless of the main policy driver for this, we really need to introduce appropriate measures to regulate the food industry, starting with managing our inability to control our intake of sugar or whatever the food industry is currently using as a substitute.…
Diabetes – Men need just right amount of sleep
Diabetes – Men need right amount of sleep! Too much or too little sleep has a negative impact on men’s health and well-being. New study shows a link between sleep and health but seems only to apply to men who have a higher risk of having diabetes. “In a group of nearly 800 healthy people,…
Evidence for comprehensive strategies tackling chronic diseases
The Joint Action CHRODIS (JA-CHRODIS) provides evidence to build comprehensive strategies to tackle diabetes and chronic diseases JA-Chrodis has launched a policy brief for World Health Day to help identify key enablers and barriers to developing implementing and sustaining National Diabetes Plans (NDPS) in Europe. The policy brief aims to support countries’ efforts to build…
Barley may increase hormones so regulating metabolism and appetite
Barley ‘increased gut hormones that regulate metabolism and appetite’ Researchers claim that the positive health effects occur when the dietary fibers in the barley kernel reach the gut, then they increase good bacteria and instigate the release of specific hormones. “After eating the bread made out of barley kernel, we saw an increase in gut…
UK: New type 2 diabetes treatment option
Type 2 diabetes drug empagliflozin Draft guidance recommends empagliflozin for treating type 2 diabetes after preliminary appraisal last August. NICE called for more evidence to demonstrate that empagliflozin was a good use of NHS resources compared with other already available treatments. Boehringer Ingelheim submitted a new cost effectiveness model showing that empagliflozin combination therapy is…